Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits

Keyphrases

• 1,3-Dichloropropene (1,3-D) 33%
• 3-D-glucan 33%
• Amphotericin B 100%
• Antifungal Efficacy 100%
• Area under the Concentration-time Curve 33%
• Aspergillus Fumigatus 33%
• Computed Tomography 33%
• Creatinine 33%
• Dose Effect 33%
• Dose Rate 33%
• Drug Clearance 33%
• Drug Levels 66%
• Echinocandins 100%
• Fumigatus 33%
• Glucan Synthase 33%
• Hepatic Transaminases 33%
• Hyphal 33%
• Improved Survival 33%
• Infarct 33%
• Invasive Pulmonary Aspergillosis 33%
• Lesion Score 33%
• Lung Weight 33%
• Maximum Permissible Concentration 33%
• Neutropenic 100%
• Pharmacokinetics 100%
• Potent Inhibitor 33%
• Pulmonary Aspergillosis 100%
• Pulmonary Injury 100%
• Pulmonary Lesions 33%
• Safety Self-efficacy 100%
• Synthetic Derivatives 33%
• Therapeutic Efficacy 33%
• Tissue Burden 33%
• Treatment Study 33%
• Truncation 33%
• Ultrafast 33%
• Vacuolization 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Aminotransferase 8%
• Amphotericin B 25%
• Anidulafungin 100%
• Antifungal Agent 100%
• Aspergillus fumigatus 8%
• Combination Therapy 8%
• Creatinine 8%
• Echinocandin B 100%
• Glucan Synthase 8%
• Infarction 8%
• Injury 8%
• Invasive Aspergillosis 8%
• Lung Aspergillosis 100%
• Lung Injury 25%
• Lung Lesion 8%
• Pharmacokinetics 100%

Immunology and Microbiology

• Aspergillus fumigatus 33%
• Blood Plasma 33%
• Body Weight 33%
• Computer Assisted Tomography 33%
• Drug Blood Level 100%
• Drug Clearance 33%
• Lung Weight 33%
• Minimum Inhibitory Concentration 66%
• Pharmacokinetics 100%